听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览PHARMACOLOGY & THERAPEUTICS期刊下所有文献
  • Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping.

    abstract::Enzymes of the UDP-glucuronosyltransferase (UGT) superfamily contribute to the elimination of drugs from almost all therapeutic classes. Awareness of the importance of glucuronidation as a drug clearance mechanism along with increased knowledge of the enzymology of drug and chemical metabolism has stimulated interest ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107689

    authors: Miners JO,Rowland A,Novak JJ,Lapham K,Goosen TC

    更新日期:2021-02-01 00:00:00

  • RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target.

    abstract::RANKL is a key molecule that bridges the bone and immune systems. RANKL stimulation activates a signaling pathway downstream of RANK, thereby determining the extent of bone resorption by inducing osteoclast maturation. The signaling pathway also regulates the development of different lymphoid organs, including the thy...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107682

    authors: Honma M,Ikebuchi Y,Suzuki H

    更新日期:2021-02-01 00:00:00

  • Therapeutic potential of targeting G protein-gated inwardly rectifying potassium (GIRK) channels in the central nervous system.

    abstract::G protein-gated inwardly rectifying potassium channels (Kir3/GirK) are important for maintaining resting membrane potential, cell excitability and inhibitory neurotransmission. Coupled to numerous G protein-coupled receptors (GPCRs), they mediate the effects of many neurotransmitters, neuromodulators and hormones cont...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2021.107808

    authors: Jeremic D,Sanchez-Rodriguez I,Jimenez-Diaz L,Navarro-Lopez JD

    更新日期:2021-01-18 00:00:00

  • Extracellular vesicles in cancer diagnostics and therapeutics.

    abstract::Cancer promotion, development, and malignant transformation is greatly influenced by cell-to-cell interactions in a complex tissue microenvironment. Cancer and stromal cells secrete soluble factors, as well as deport membrane-encapsulated structures, which actively contribute and mediate cell-to-cell interaction withi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2021.107806

    authors: Shehzad A,Islam SU,Shahzad R,Khan S,Lee YS

    更新日期:2021-01-16 00:00:00

  • Cocaine use disorder: A look at metabotropic glutamate receptors and glutamate transporters.

    abstract::Glutamate transmission is an important mediator of the development of substance use disorders, particularly with regard to relapse. The present review summarizes the changes in glutamate levels in the reward system (the prefrontal cortex, nucleus accumbens, dorsal striatum, hippocampus, and ventral tegmental area) obs...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107797

    authors: Niedzielska-Andres E,Pomierny-Chamioło L,Andres M,Walczak M,Knackstedt LA,Filip M,Przegaliński E

    更新日期:2021-01-09 00:00:00

  • Role of inflammatory chemokines in hypertension.

    abstract::Hypertension is associated with immune cells activation and their migration into the kidney, vasculature, heart and brain. These inflammatory mechanisms are critical for blood pressure regulation and mediate target organ damage, creating unique novel targets for pharmacological modulation. In response to angiotensin I...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107799

    authors: Mikolajczyk TP,Szczepaniak P,Vidler F,Maffia P,Graham GJ,Guzik TJ

    更新日期:2020-12-24 00:00:00

  • Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency.

    abstract::Glucose-6-phospate dehydrogenase (G6PD) deficiency is estimated to affect more than 400 million people world-wide. This X-linked genetic deficiency puts stress on red blood cells (RBC), which may be further augmented under certain pathophysiological conditions and drug treatments. These conditions can cause hemolytic ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107788

    authors: Ryan K,Tekwani BL

    更新日期:2020-12-14 00:00:00

  • Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing.

    abstract::Artemisinins are a unique class of antimalarial drugs with significant potential for drug repurposing for a wide range of diseases including cancer. Cancer is a leading cause of death globally and the majority of cancer related deaths occur in Low and Middle Income Countries (LMICs) where conventional treatment option...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107706

    authors: Augustin Y,Staines HM,Krishna S

    更新日期:2020-12-01 00:00:00

  • The birth of artemisinin.

    abstract::As the first-line antimalarial drugs, artemisinins gained wide acceptance after the emergence of resistance to chloroquine in the 1950s. Artemisinin-based drugs have saved lives, especially in developing countries. The discovery of artemisinin was unique, timely, and fascinating, and the benefits of artemisinin were w...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107658

    authors: Ma N,Zhang Z,Liao F,Jiang T,Tu Y

    更新日期:2020-12-01 00:00:00

  • Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.

    abstract::The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angiotensin-converting ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107628

    authors: Wang JJ,Edin ML,Zeldin DC,Li C,Wang DW,Chen C

    更新日期:2020-11-01 00:00:00

  • Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis.

    abstract::RSV infection of the lower respiratory tract in infants is the leading cause of pediatric hospitalizations and second to malaria in causing infant deaths worldwide. RSV also causes substantial morbidity in immunocompromised and elderly populations. The only available therapeutic is a prophylactic drug called Palivizum...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107712

    authors: Elawar F,Oraby AK,Kieser Q,Jensen LD,Culp T,West FG,Marchant DJ

    更新日期:2020-10-27 00:00:00

  • PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders.

    abstract::Neurodegenerative diseases represent some of the most devastating neurological disorders, characterized by progressive loss of the structure and function of neurons. Current therapy for neurodegenerative disorders is limited to symptomatic treatment rather than disease modifying interventions, emphasizing the desperat...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107705

    authors: Jamwal S,Blackburn JK,Elsworth JD

    更新日期:2020-10-09 00:00:00

  • Targeting peroxisome proliferator-activated receptors: A new strategy for the treatment of cardiac fibrosis.

    abstract::Cardiac fibrosis is a pathogenic factor of many cardiovascular diseases (CVD), which seriously affects people's life, and health and causes huge economic losses. Increasing evidence has shown that peroxisome proliferator-activated receptors (PPARs) can regulate the progression of cardiac fibrosis. For the first time, ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107702

    authors: Lu Q,Guo P,Guo J,Ares I,Lopez-Torres B,Martínez-Larrañaga MR,Wang X,Anadón A,Martínez MA

    更新日期:2020-10-04 00:00:00

  • Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

    abstract::Dopamine D2 autoreceptors (D2ARs), located in somatodendritic and axon terminal compartments of dopamine (DA) neurons, function to provide a negative feedback regulatory control on DA neuron firing, DA synthesis, reuptake and release. Dysregulation of D2AR-mediated DA signaling is implicated in vulnerability to substa...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107583

    authors: Chen R,Ferris MJ,Wang S

    更新日期:2020-09-01 00:00:00

  • Long noncoding RNA loss in immune suppression in cancer.

    abstract::Long noncoding RNAs (lncRNAs) have multiple functions in the regulation of cellular homeostasis. In recent years, numerous studies have shown that tumor-associated lncRNAs play key roles in promoting and maintaining tumor initiation and progression by shaping the tumor microenvironment through changing tumor cell intr...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107591

    authors: Hu Q,Egranov SD,Lin C,Yang L

    更新日期:2020-09-01 00:00:00

  • PARP inhibition in the ovarian cancer patient: Current approvals and future directions.

    abstract::Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic management of solid tumors, particularly ovarian cancer. Initially studied in BRCA deficient tumors, the Food and Drug Administration (FDA) indications have expanded to include other homologous recombination deficient tumors as well as bio...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107588

    authors: Kurnit KC,Avila M,Hinchcliff EM,Coleman RL,Westin SN

    更新日期:2020-09-01 00:00:00

  • MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.

    abstract::The receptor tyrosine kinase MERTK is aberrantly expressed in numerous human malignancies, and is a novel target in cancer therapeutics. Physiologic roles of MERTK include regulation of tissue homeostasis and repair, innate immune control, and platelet aggregation. However, aberrant expression in a wide range of liqui...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107577

    authors: Huelse JM,Fridlyand DM,Earp S,DeRyckere D,Graham DK

    更新日期:2020-09-01 00:00:00

  • Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.

    abstract::The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional C...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107587

    authors: Liu T,Luo S,Libby P,Shi GP

    更新日期:2020-09-01 00:00:00

  • VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.

    abstract::Hyperkinetic movement disorders comprise a variety of conditions characterized by involuntary movements, which include but are not limited to tardive dyskinesia, chorea associated with Huntington's Disease, and tic disorders. The class of medications that have been used to treat these conditions includes Vesicular Mon...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107580

    authors: Koch J,Shi WX,Dashtipour K

    更新日期:2020-08-01 00:00:00

  • Applications of personalised signalling network models in precision oncology.

    abstract::As our ability to provide in-depth, patient-specific characterisation of the molecular alterations within tumours rapidly improves, it is becoming apparent that new approaches will be required to leverage the power of this data and derive the full benefit for each individual patient. Systems biology approaches are beg...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107555

    authors: Hastings JF,O'Donnell YEI,Fey D,Croucher DR

    更新日期:2020-08-01 00:00:00

  • Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.

    abstract::Chemoresistance, radioresistance, and the challenge of achieving complete resection are major driving forces in the search for more robust and targeted anticancer therapies. Targeting the DNA damage response has recently attracted research interest, as these processes are enhanced in tumour cells. The major replicatio...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107518

    authors: Gorecki L,Andrs M,Rezacova M,Korabecny J

    更新日期:2020-06-01 00:00:00

  • Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.

    abstract::Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza drug in Japan. Additionally, favipiravir is being stockpiled for 2 million people as a countermeasure for novel influenza strains. This drug functions as a chain terminator at the site of incorporation of the viral RNA and reduc...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107512

    authors: Shiraki K,Daikoku T

    更新日期:2020-05-01 00:00:00

  • Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?

    abstract::Metabolic diseases have a tremendous impact on human morbidity and mortality. Numerous targets regulating adenosine monophosphate kinase (AMPK) have been identified for treating the metabolic syndrome (MetS), and many compounds are being used or developed to increase AMPK activity. In parallel, the cyclic nucleotide p...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107475

    authors: Lugnier C,Meyer A,Talha S,Geny B

    更新日期:2020-04-01 00:00:00

  • Immunotherapy in sepsis - brake or accelerate?

    abstract::Sepsis, a life threating syndrome characterized by organ failure after infection, is the most common cause of death in hospitalized patients. The treatment of sepsis is generally supportive in nature, involving the administration of intravenous fluids, vasoactive substances and oxygen plus antibiotics to eliminate the...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107476

    authors: Steinhagen F,Schmidt SV,Schewe JC,Peukert K,Klinman DM,Bode C

    更新日期:2020-04-01 00:00:00

  • Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.

    abstract::Chemotherapy, surgery, and radiation are accepted as the preferred treatment modalities against cancer, but in recent years the use of immunotherapeutic approaches has gained prominence as the fourth treatment modality in cancer patients. In this approach, a patient's innate and adaptive immune systems are activated t...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.107456

    authors: Gorbet MJ,Ranjan A

    更新日期:2020-03-01 00:00:00

  • Use of glucocorticoids in the critical care setting: Science and clinical evidence.

    abstract::Glucocorticoids (GC) in all its various forms and formulations are likely one of the most commonly used pharmacologic agents in medicine. Their use can be profoundly therapeutic but are also associated with a myriad of acute and chronic side effects. It is fairly well-accepted in the medical community that GC can be l...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.107428

    authors: Chan ED,Chan MM,Chan MM,Marik PE

    更新日期:2020-02-01 00:00:00

  • Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.

    abstract::The selective 5-HT2C receptor agonist lorcaserin, in conjunction with lifestyle modification, was approved by the FDA in 2012 for weight management. It has been marketed in the US as Belviq® since 2013. This article provides a review of the preclinical and clinical pharmacology of lorcaserin, including its pharmacokin...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.107417

    authors: Higgins GA,Fletcher PJ,Shanahan WR

    更新日期:2020-01-01 00:00:00

  • Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.

    abstract::Neutrophils form an essential part of innate immunity against infection. Cancer chemotherapy-induced neutropenia (CCIN) is a condition in which the number of neutrophils in a patient's bloodstream is decreased, leading to increased susceptibility to infection. Granulocyte colony-stimulating factor (GCSF) has been the ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.107403

    authors: Abdel-Azim H,Sun W,Wu L

    更新日期:2019-12-01 00:00:00

  • Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases.

    abstract::Chitinase 3-like 1 (CHI3L1) is a secreted glycoprotein that mediates inflammation, macrophage polarization, apoptosis, and carcinogenesis. The expression of CHI3L1 is strongly increased by various inflammatory and immunological conditions, including rheumatoid arthritis, multiple sclerosis, Alzheimer's disease, and se...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.107394

    authors: Yeo IJ,Lee CK,Han SB,Yun J,Hong JT

    更新日期:2019-11-01 00:00:00

  • Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics.

    abstract::Destruction of the established tumour vasculature by a class of compound termed Vascular Disrupting Agents (VDAs) is showing considerable promise as a viable approach for the management of solid tumours. VDAs induce a rapid shutdown and collapse of tumour blood vessels, leading to ischaemia and consequent necrosis of ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.06.001

    authors: Gill JH,Rockley KL,De Santis C,Mohamed AK

    更新日期:2019-10-01 00:00:00

  • Mesenchymal stem cells: From regeneration to cancer.

    abstract::Mesenchymal stem cells (MSCs) are multipotent tissue stem cells that differentiate into a number of mesodermal tissue types, including osteoblasts, adipocytes, chondrocytes and myofibroblasts. MSCs were originally identified in the bone marrow (BM) of humans and other mammals, but recent studies have shown that they a...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.04.005

    authors: Li P,Gong Z,Shultz LD,Ren G

    更新日期:2019-08-01 00:00:00

  • Intestinal microbiome as a novel therapeutic target for local and systemic inflammation.

    abstract::Recently, the pathogenesis of systemic inflammatory disease such as inflammatory bowel disease (IBD), multiple sclerosis (MS), systemic inflammatory arthritis, asthma, and non-alcoholic fatty liver disease has been reported to be related to the dysbiosis of gut microbiota. The contribution of special bacteria for the ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.03.006

    authors: Uchiyama K,Naito Y,Takagi T

    更新日期:2019-07-01 00:00:00

  • Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

    abstract::The purpose of this paper is to provide an integrative review and offer novel insights regarding human research with classic psychedelics (classic hallucinogens), which are serotonin 2A receptor (5-HT2AR) agonists such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Classic psychedelics have been admin...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.11.010

    authors: Johnson MW,Hendricks PS,Barrett FS,Griffiths RR

    更新日期:2019-05-01 00:00:00

  • KIT as a therapeutic target for non-oncological diseases.

    abstract::KIT is a receptor tyrosine kinase that after binding to its ligand stem cell factor activates signaling cascades linked to biological processes such as proliferation, differentiation, migration and cell survival. Based on studies performed on SCF and/or KIT mutant animals that presented anemia, sterility, and/or pigme...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.12.008

    authors: Martinez-Anton A,Gras D,Bourdin A,Dubreuil P,Chanez P

    更新日期:2019-05-01 00:00:00

  • HMGB1 and repair: focus on the heart.

    abstract::High-mobility group box 1 (HMGB1) is one of the most abundant proteins in eukaryotes and the best characterized damage-associated molecular pattern (DAMP). The biological activities of HMGB1 depend on its subcellular location, context and post-translational modifications. Inside the nucleus, HMGB1 is engaged in many D...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.12.005

    authors: Pellegrini L,Foglio E,Pontemezzo E,Germani A,Russo MA,Limana F

    更新日期:2019-04-01 00:00:00

  • The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy.

    abstract::Sphingolipid metabolites, such as ceramide, sphingosine and sphingosine-1-phosphate (S1P), play many important roles in cellular activities. Ceramide and sphingosine inhibit cell proliferation and induce cell apoptosis while S1P has the opposite effect. Maintaining a metabolic balance of sphingolipids is essential for...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.10.011

    authors: Zheng X,Li W,Ren L,Liu J,Pang X,Chen X,Kang,Wang J,Du G

    更新日期:2019-03-01 00:00:00

  • TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward.

    abstract::The use of Translocator Protein 18 kDa (TSPO) as a clinical neuroimaging biomarker of brain injury and neuroinflammation has increased exponentially in the last decade. There has been a furious pace in the development of new radiotracers for TSPO positron emission tomography (PET) imaging and its use has now been exte...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.09.003

    authors: Guilarte TR

    更新日期:2019-02-01 00:00:00

  • The role of flavonoids in autoimmune diseases: Therapeutic updates.

    abstract::Flavonoids are natural polyphenolic compounds which are included in a panoply of drugs and used to treat and/or manage human ailments such as metabolic, cardiovascular, neurological disorders and cancer. Thus, the purpose of this review is to emphasize the importance of flavonoids for the treatment of autoimmune disea...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.09.009

    authors: Rengasamy KRR,Khan H,Gowrishankar S,Lagoa RJL,Mahomoodally FM,Khan Z,Suroowan S,Tewari D,Zengin G,Hassan STS,Pandian SK

    更新日期:2019-02-01 00:00:00

  • Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.

    abstract::Targeted therapies have changed the landscape of treatments for non-small cell lung cancer (NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring genetic alterations in four oncogenes, and agents targeting additional oncogenic drivers are under investigation. Standard first-line chemother...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.08.007

    authors: Yoda S,Dagogo-Jack I,Hata AN

    更新日期:2019-01-01 00:00:00

  • Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis.

    abstract::Cardiovascular disease (CVD) continues to be a leading cause of death worldwide with atherosclerosis being the major underlying pathology. The interplay between lipids and immune cells is believed to be a driving force in the chronic inflammation of the arterial wall during atherogenesis. Atherosclerosis is initiated ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.08.012

    authors: Lacy M,Atzler D,Liu R,de Winther M,Weber C,Lutgens E

    更新日期:2019-01-01 00:00:00

303 条记录 1/8 页 « 12345678 »